A5058986182- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Prostate Cancer Diagnosis and Treatment
- Hormonal and reproductive studies
- Neuroendocrine Tumor Research Advances
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- RNA modifications and cancer
- Inflammatory Biomarkers in Disease Prognosis
Institut Gustave Roussy
2016-2025
UniCancer Group
2025
Université Paris-Saclay
2017-2024
Inserm
1991-2024
Institut de Recherche contre les Cancers de l’Appareil Digestif
2023
Université Paris-Sud
2017-2021
Délégation Paris 5
2016
Université Paris Cité
2016
Assistance Publique – Hôpitaux de Paris
2016
Veolia (Norway)
2013
Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine inhibitor with proven efficacy in patients ALK-rearranged lung cancer previously treated first- and second-generation ALK inhibitors. Beside compound mutations the domain, other resistance mechanisms driving lorlatinib remain unknown. We aimed to characterize of occurring design new therapeutic strategies this setting.Resistance were investigated 5 resistant lorlatinib. Longitudinal tumor biopsies studied using...
<h3>Importance</h3> DNA repair gene aberrations occur in 20% to 30% of patients with castration-resistant prostate cancer (CRPC), and some these have been associated sensitivity poly(ADP-ribose) polymerase (PARP) inhibition or platinum-based treatments. However, previous trials assessing treatments CRPC mostly included a biomarker-unselected population; therefore, efficacy is unknown. <h3>Objective</h3> To characterize the antitumor activity therapies men without alterations. <h3>Design,...
Neoadjuvant immune checkpoint inhibitors induce major pathologic response (MPR) rates in 17- 45% of NSCLCs. We report the results a phase 2 trial neoadjuvant A for NSCLC. Patient (pts) with clinical stage IA (≥ cm)-IIIA non N2 NSCLC eligible surgery, PS 0-1, received 1 injection (1200 mg IV D1) followed by surgery between D21-D28. The primary endpoint was rate pts without toxicities or morbidities from D1 until month after surgery. Fresh tumour tissue analysed within 4 hours Response...
Background: Baseline steroids before ICI have been associated with poor outcomes, particularly when introduced due to cancer symptoms. Methods: Retrospective analysis of advanced NSCLC patients treated ICI. We collected the use intercurrent (≥10 mg prednisone-equivalent) within first eight weeks correlated steroid patient outcomes according indications. Results: 413 received ICI, 299 were steroids-naïve at baseline. A total 49 (16%), whom 38 for cancer-related symptoms and 11 other...
Prostate cancer is one of the most common cancers in men and fourth leading cause mortality worldwide. Although major progress has been achieved last years for patients with metastatic castrate-resistant prostate (mCRPC), thanks to next-generation androgen receptor axis targeted drugs, taxanes, bone-targeted agents, immunotherapy not widely approved used treatment cancer. Two large studies ipilimumab, an anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) antibody reported improved...
Few prognostic factors have been identified in patients with metastatic urothelial carcinoma (mUC) treated immune checkpoint inhibitors (ICIs). The Lung Immune Prognostic Index (LIPI) was associated clinical outcomes for ICIs several tumor types. We aim to assess the value of LIPI mUC ICIs. A retrospective ICI cohort and a validation (SAUL cohort) included, respectively, 8 European centers (any line) atezolizumab second or further line. chemotherapy-only also analyzed. score based on 2...
The androgen receptor axis inhibitors (ARPI; e.g., enzalutamide, abiraterone acetate) are administered in daily practice for men with metastatic castration-resistant prostate cancer (mCRPC). However, not all patients respond, and mechanisms of both primary acquired resistance remain largely unknown.In the prospective trial MATCH-R (NCT02517892), 59 mCRPC underwent whole-exome sequencing (WES) and/or RNA (RNA-seq) samples collected before starting ARPI. Also, 18 biopsy at time resistance....
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers this setting. We aimed to develop disease-specific index for a/mUC patients on ICIs. Methods: Fifteen variables were retrospectively correlated with OS and progression-free (PFS) development (D, n = 264) validation (V, 132) cohort platinum-pretreated pts receiving ICIs at L2 or...
The efficacy of front-line pembrolizumab has been established in studies that limit treatment duration to 2 years, but decision stop after years is often at physician's discretion. ATHENA a retrospective cohort study using comprehensive administrative database aimed firstly exploring the optimal and secondly real-life prognosis factors patients with advanced non-small cell lung cancer (NSCLC). Using French National Health Insurance (SNDS), we identified incident France from 2015 2022....
Background The MOVIE phase I/II trial ( NCT03518606 ) evaluated the safety and antitumor activity of durvalumab tremelimumab combined with metronomic oral vinorelbine in patients advanced tumors. We present results recurrent cervical cancer cohort. Methods Patients received (intravenously, 75 mg, every four weeks (Q4W); cycles max) plus 1,500 Q4W; 26 (40 three (3QW)) until disease progression. primary efficacy endpoint was clinical benefit rate (CBR) based on Response Evaluation Criteria...
<title>Abstract</title> Immune checkpoint inhibitors (ICI) are a class of immunotherapy drugs that have shown significant success in treating various types cancers. However, their effectiveness prostate cancer (PC) has been more challenging due to an immunosuppressive tumor microenvironment. Low-dose metronomic chemotherapy immunomodulatory properties could enhance and is well-tolerated. MOVIE was phase 1/2 multi-cohort study with Bayesian design evaluated the antitumor activity safety...
Abstract Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating antitumor activity inhibitors rearrangement-positive are limited. Here, a pan-cancer analysis &gt;46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic rearrangements ~0.04% cancers. Preliminary from phase 2 trial type I...
Abstract Introduction: Despite the success of immune checkpoint blockers (ICBs), predicting which patients will respond to treatment remains a significant challenge, particularly in those with advanced NSCLC. Some circulating antibodies may serve as indicators pre-existing antitumor adaptive response. This study investigated potential baseline serum predictors response and survival NSCLC undergoing ICB, chemotherapy, or ICB + chemotherapy. Materials Methods: Baseline samples were collected...
Abstract Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) have immunomodulatory properties that may potentiate anti-PD-L1 therapy. The academic phase 2 basket trial ARIANES evaluated the PARPi rucaparib (R) and atezolizumab (A) in selected patients (pts). We performed single-cell RNA + T-cell receptor sequencing (scRNA+TCR-Seq) bulk RNA-Seq on sequential tumor biopsies, concomitant plasma proteomics, whole exome a pt subset. Methods: included 4 molecularly DNA damage response...
Unravelling the biological processes driving tumour resistance is necessary to support development of innovative treatment strategies. We report design and feasibility MATCH-R prospective trial led by Gustave Roussy with primary objective characterizing molecular mechanisms cancer treatments. The clinical endpoints consist analyzing type frequency alterations in resistant tumours compare these samples prior treatment. Patients experiencing disease progression after an initial partial...
Abstract Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic Lymphoma Kinase ( ALK )-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) relevant tools identify additional mechanisms and can be sequenced single-cell level. Here, we provide in-depth investigation copy number alteration (CNA) heterogeneity phenotypically characterized CTCs ALK-TKIs -positive non-small cell lung cancer. Single CTC isolation phenotyping were performed by...